IngentaConnect Effect of gliclazide modified release on adiponectin, interleukin...

Abstract:

Objective: The aim of the study was to evaluate the effect of gliclazide modified release (MR) treatment on adiponectin, interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α) plasma concentrations in type 2 diabetic patients.

Research design and methods: 24 randomly selected type 2 diabetic patients, aged 61.2 ± 15.4 years, with poorly controlled glucose level (mean glycated hemoglobin [HbA_1c] 7.6 ± 1.1%) despite treatment with diet and/or oral hypoglycemic agents, were included in the study. All of the patients, after a 2-week run-in period, were given gliclazide MR for 12 weeks. At baseline, and after gliclazide MR treatment, HbA_1c and plasma concentrations of IL-6, TNF-α, and adiponectin were measured.

Results: Gliclazide MR treatment produced significant reductions in fasting plasma glucose (from 7.6 ± 1.4 to 6.6 ± 1.2 mmol/L, p < 0.01), HbA_1c (from 7.6 ± 1.1 to 6.9 ± 0.8%, p < 0.01), and plasma IL-6 concentrations (from 2.5 ± 1.8 to 1.8 ± 1.2 pg/mL, p < 0.05). A significant increase in plasma adiponectin level was noted (from 6.4 ± 3.3 to 7.6 ± 4.4 μg/mL, p < 0.05). Plasma TNF-α concentrations and homeostasis model assessment of insulin resistance (HOMA-IR) decreased after treatment, but these changes did not reach statistical significance.

Conclusions: Gliclazide MR improves glycemic control and, in addition, has a positive influence on the plasma level of some inflammatory markers and adiponectin. Increased plasma adiponectin and decreased plasma IL-6, and TNF-α levels may explain, at least in part, the anti-atherogenic action of this drug reported elsewhere.

Keywords: ADIPONECTIN; GLICLAZIDE MODIFIED RELEASE; INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA

Document Type: Short communication

DOI: 10.1185/030079906X132424

Affiliations: 1: Department of Internal Medicine, Diabetology and Clinical Pharmacology, Medical University of Łódź, Poland

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$51.50 plus tax

Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-α plasma levels in individuals with type 2 diabetes mellitus